This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass Inc.'s research and development efforts to advance this innovative biologic therapy through preclinical and potential early clinical testing. The Military Medical Research and Development program supports a range of biomedical research to improve health outcomes for military service members, veterans, and their families, with a focus on high-impact, transformative projects.
Generated 11/26/24, 4:56 AM